RODMAN&RENSHAW Analyst Recommendations & Stock Picks This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at RODMAN&RENSHAW. These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by RODMAN&RENSHAW. Brokerage RatingSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROITotal Ratings23 Last 12 MonthsBuy Ratings21 Last 12 MonthsSell Ratings0 Last 12 MonthsCompanies Covered22 Last 12 Months Country USA (NYSE & NASDAQ) USA (NYSE & NASDAQ)USA (All Exchanges)CanadaUnited Kingdom Sector All Sectors AerospaceAuto/Tires/TrucksBasic MaterialsBusiness ServicesCommunication ServicesComputer and TechnologyConstructionConsumer CyclicalConsumer DefensiveConsumer DiscretionaryConsumer GoodsConsumer StaplesEnergyFinanceFinancial ServicesIndustrialsManufacturingMedicalMiscellaneousMulti-Sector ConglomeratesReal EstateRetail/WholesaleServicesTransportationUtilities Market Cap All MarketCaps Mega Cap (More Than $200B)Large Cap ($10B-$200B)Mid Cap ($2B-$10B)Small Cap ($300M-$2B)Micro Cap ($50M-$300M)Nano Cap (Under $50M) MarketRank™ evaluates a company based on dividend strength, earnings, valuation, analysts forecasts, and more.Available with a MarketBeat All Access SubscriptionMarketRank™Upgrade to All Access to use the All Ranks Filter Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.Available with a MarketBeat All Access SubscriptionMedia SentimentUpgrade to All Access to use the All Sentiments Filter Analyst consensus is the average investment recommendation among Wall Street research analysts.Available with a MarketBeat All Access SubscriptionAnalyst ConsensusUpgrade to All Access to use the All Ratings Filter Reporting Date Export to Excel CompanyCurrent PriceReport DateAnalystActionPrice TargetRating12-Month Recommendation ROIDetailsBTAIBioXcel Therapeutics$3.79+6.2%3/19/2025E. PirosSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-Buy00.00%View details for RODMAN&RENSHAW rating of BioXcel Therapeutics (NASDAQ:BTAI) on 3/19/2025TELOTelomir Pharmaceuticals$1.242/20/2025E. PirosSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-Buy00.00%View details for RODMAN&RENSHAW rating of Telomir Pharmaceuticals (NASDAQ:TELO) on 2/20/2025TLPHTalphera$0.55+6.5%1/28/2025B. FolkesSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-Buy00.00%View details for RODMAN&RENSHAW rating of Talphera (NASDAQ:TLPH) on 1/28/2025PYPDPolyPid$3.45+1.5%1/28/2025B. FolkesSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-Buy00.00%View details for RODMAN&RENSHAW rating of PolyPid (NASDAQ:PYPD) on 1/28/2025INMBINmune Bio$1.95+1.6%1/28/2025E. PirosSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-Buy00.00%View details for RODMAN&RENSHAW rating of INmune Bio (NASDAQ:INMB) on 1/28/2025CRDLCardiol Therapeutics$1.09-1.8%1/28/2025B. FolkesSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-Buy00.00%View details for RODMAN&RENSHAW rating of Cardiol Therapeutics (NASDAQ:CRDL) on 1/28/2025ATRAAtara Biotherapeutics$12.91+0.9%1/21/2025T. ButlerSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold00.00%View details for RODMAN&RENSHAW rating of Atara Biotherapeutics (NASDAQ:ATRA) on 1/21/2025ATRAAtara Biotherapeutics$12.91+0.9%12/20/2024T. ButlerSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-Buy00.00%View details for RODMAN&RENSHAW rating of Atara Biotherapeutics (NASDAQ:ATRA) on 12/20/2024HURATuHURA Biosciences$2.55+0.8%12/19/2024T. ButlerSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-Buy00.00%View details for RODMAN&RENSHAW rating of TuHURA Biosciences (NASDAQ:HURA) on 12/19/2024THARTharimmune$3.68-7.8%12/6/2024E. PirosSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-Buy00.00%View details for RODMAN&RENSHAW rating of Tharimmune (NASDAQ:THAR) on 12/6/2024RMTIRockwell Medical$1.62-3.6%11/14/2024B. FolkesSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-Buy00.00%View details for RODMAN&RENSHAW rating of Rockwell Medical (NASDAQ:RMTI) on 11/14/2024OMEROmeros$4.17-0.2%11/14/2024B. FolkesSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-Buy00.00%View details for RODMAN&RENSHAW rating of Omeros (NASDAQ:OMER) on 11/14/2024EPRXEupraxia Pharmaceuticals$5.39+0.6%11/14/2024B. FolkesSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-Buy00.00%View details for RODMAN&RENSHAW rating of Eupraxia Pharmaceuticals (NASDAQ:EPRX) on 11/14/2024ACHVAchieve Life Sciences$2.83+1.4%11/14/2024B. FolkesSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-Buy00.00%View details for RODMAN&RENSHAW rating of Achieve Life Sciences (NASDAQ:ACHV) on 11/14/2024BCAXBicara Therapeutics$12.0611/5/2024T. ButlerSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-Buy00.00%View details for RODMAN&RENSHAW rating of Bicara Therapeutics (NASDAQ:BCAX) on 11/5/2024QNCXQuince Therapeutics$1.61+0.3%10/29/2024E. PirosSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-Buy00.00%View details for RODMAN&RENSHAW rating of Quince Therapeutics (NASDAQ:QNCX) on 10/29/2024ANROAlto Neuroscience$3.65+3.8%10/23/2024E. PirosSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold00.00%View details for RODMAN&RENSHAW rating of Alto Neuroscience (NYSE:ANRO) on 10/23/2024NKTXNkarta$2.26+6.1%10/9/2024T. ButlerSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-Buy00.00%View details for RODMAN&RENSHAW rating of Nkarta (NASDAQ:NKTX) on 10/9/2024KYTXKyverna Therapeutics$3.94+8.5%10/9/2024T. ButlerSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-Buy00.00%View details for RODMAN&RENSHAW rating of Kyverna Therapeutics (NASDAQ:KYTX) on 10/9/2024MIRAMIRA Pharmaceuticals$1.40+1.4%9/30/2024E. PirosSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-Buy00.00%View details for RODMAN&RENSHAW rating of MIRA Pharmaceuticals (NASDAQ:MIRA) on 9/30/2024BMEABiomea Fusion$1.92+4.9%9/26/2024T. ButlerSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-Buy00.00%View details for RODMAN&RENSHAW rating of Biomea Fusion (NASDAQ:BMEA) on 9/26/2024 MarketBeat Community Rating for RODMAN&RENSHAWCommunity Ranking: 2.5 out of 5 (2.5 of 5 stars)Outperform Votes: 23,290 (Thanks for Voting!)Underperform Votes: 23,928 (Thanks for Voting!)Total Votes: 47,218MarketBeat's community ratings are surveys of what our community members think about RODMAN&RENSHAW and other research firms. Vote "Outperform" if you believe RODMAN&RENSHAW's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RODMAN&RENSHAW's recommendations will underperform the S&P 500 over the long term. You may vote once every thirty days. Stock Forecasts and Research Tools Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
